149 related articles for article (PubMed ID: 33242523)
1. Antigenicity study of the yeast-generated human parvovirus 4 (PARV4) virus-like particles.
Lazutka J; Simutis K; Matulis P; Petraitytė-Burneikienė R; Kučinskaitė-Kodzė I; Simanavičius M; Tamošiunas PL
Virus Res; 2021 Jan; 292():198236. PubMed ID: 33242523
[TBL] [Abstract][Full Text] [Related]
2. Production of human parvovirus 4 VP2 virus-like particles in yeast and their evaluation as an antigen for detection of virus-specific antibodies in human serum.
Tamošiūnas PL; Simutis K; Kodzė I; Firantienė R; Emužytė R; Petraitytė-Burneikienė R; Zvirblienė A; Sasnauskas K
Intervirology; 2013; 56(5):271-7. PubMed ID: 23941824
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of virus-like particles containing modified goose parvovirus VP2 protein.
Chen Z; Li C; Zhu Y; Wang B; Meng C; Liu G
Virus Res; 2012 Oct; 169(1):306-9. PubMed ID: 22940567
[TBL] [Abstract][Full Text] [Related]
4. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
5. Potent neutralization activity against type O foot-and-mouth disease virus elicited by a conserved type O neutralizing epitope displayed on bovine parvovirus virus-like particles.
Chang J; Zhang Y; Yang D; Jiang Z; Wang F; Yu L
J Gen Virol; 2019 Feb; 100(2):187-198. PubMed ID: 30547855
[TBL] [Abstract][Full Text] [Related]
6. Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles.
Simanavicius M; Tamosiunas PL; Petraityte-Burneikiene R; Johne R; Ulrich RG; Zvirbliene A; Kucinskaite-Kodze I
Appl Microbiol Biotechnol; 2018 Jan; 102(1):185-198. PubMed ID: 29143081
[TBL] [Abstract][Full Text] [Related]
7. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.
Sharp CP; Lail A; Donfield S; Simmons R; Leen C; Klenerman P; Delwart E; Gomperts ED; Simmonds P
J Infect Dis; 2009 Oct; 200(7):1119-25. PubMed ID: 19691429
[TBL] [Abstract][Full Text] [Related]
8. Peptide presentation on primate erythroparvovirus 1 virus-like particles: In vitro assembly, stability and immunological properties.
Del Carmen Morán-García A; Rivera-Toledo E; Echeverría O; Vázquez-Nin G; Gómez B; Bustos-Jaimes I
Virus Res; 2016 Sep; 224():12-8. PubMed ID: 27523978
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
10. Generation of recombinant porcine parvovirus virus-like particles in Saccharomyces cerevisiae and development of virus-specific monoclonal antibodies.
Tamošiūnas PL; Petraitytė-Burneikienė R; Lasickienė R; Akatov A; Kundrotas G; Sereika V; Lelešius R; Žvirblienė A; Sasnauskas K
J Immunol Res; 2014; 2014():573531. PubMed ID: 25045718
[TBL] [Abstract][Full Text] [Related]
11. Large-scale manufacture of VP2 VLP vaccine against porcine parvovirus in Escherichia coli with high-density fermentation.
Wang J; Liu Y; Chen Y; Wang A; Wei Q; Liu D; Zhang G
Appl Microbiol Biotechnol; 2020 May; 104(9):3847-3857. PubMed ID: 32130468
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immune responses induced by porcine parvovirus virus-like particles and inactivated vaccine.
Tian W; Qiu Z; Cui Y; Zhang J; Ma X; Cui S; Zheng S
Pak J Pharm Sci; 2019 Jan; 32(1(Special)):377-382. PubMed ID: 30852473
[TBL] [Abstract][Full Text] [Related]
13. Trigger factor assisted self-assembly of canine parvovirus VP2 protein into virus-like particles in Escherichia coli with high immunogenicity.
Nan L; Liu Y; Ji P; Feng H; Chen C; Wang J; Liu D; Cui Y; Wang Y; Li Y; Zhou E; Zhang G
Virol J; 2018 Jun; 15(1):103. PubMed ID: 29921294
[TBL] [Abstract][Full Text] [Related]
14. Parvovirus PARV4 visualization and detection.
Tuke PW; Parry RP; Appleton H
J Gen Virol; 2010 Feb; 91(Pt 2):541-4. PubMed ID: 19846677
[TBL] [Abstract][Full Text] [Related]
15. Influence of minor displacements in loops of the porcine parvovirus VP2 capsid on virus-like particles assembly and the induction of antibody responses.
Pan Q; He K; Wang Y; Wang X; Ouyang W
Virus Genes; 2013 Jun; 46(3):465-72. PubMed ID: 23430711
[TBL] [Abstract][Full Text] [Related]
16. Generation of a parvovirus B19 vaccine candidate.
Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
[TBL] [Abstract][Full Text] [Related]
17. Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen.
Pleckaityte M; Bremer CM; Gedvilaite A; Kucinskaite-Kodze I; Glebe D; Zvirbliene A
BMC Biotechnol; 2015 Sep; 15():85. PubMed ID: 26370129
[TBL] [Abstract][Full Text] [Related]
18. Reduction of Postweaning Multisystemic Wasting Syndrome-Associated Clinical Symptoms by Virus-Like Particle Vaccine Against Porcine Parvovirus and Porcine Circovirus Type 2.
Liu G; Qiao X; Chang C; Hua T; Wang J; Tang B; Zhang D
Viral Immunol; 2020; 33(6):444-456. PubMed ID: 32255758
[TBL] [Abstract][Full Text] [Related]
19. Development and evaluation of a competitive ELISA using a monoclonal antibody for antibody detection after goose parvovirus virus-like particles (VLPs) and vaccine immunization in goose sera.
Wang Q; Ju H; Li Y; Jing Z; Guo L; Zhao Y; Ma B; Gao M; Zhang W; Wang J
J Virol Methods; 2014 Dec; 209():69-75. PubMed ID: 25196452
[TBL] [Abstract][Full Text] [Related]
20. Yeast-generated virus-like particles as antigens for detection of human bocavirus 1-4 specific antibodies in human serum.
Tamošiūnas PL; Petraitytė-Burneikienė R; Bulavaitė A; Marcinkevičiūtė K; Simutis K; Lasickienė R; Firantienė R; Ėmužytė R; Žvirblienė A; Sasnauskas K
Appl Microbiol Biotechnol; 2016 Jun; 100(11):4935-46. PubMed ID: 26846623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
